Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anette Duensing

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Scientific Reports|May 18, 2022
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerabilityDonna M Lee, Angela Sun, Sneha S Patil, et al.
Scientific Reports|March 22, 2020
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cellsJessica L Rausch, Areej A Ali, Donna M Lee, et al.
Clinical Sarcoma Research|March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
Urologic Oncology|July 18, 2020
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53Adam Kaczorowski, Yanis Tolstov, Michael Falkenstein, et al.
Cancer Research|January 4, 2014
Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumorsSergei Boichuk, Derek J Lee, Keith R Mehalek, et al.
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
Urologic Oncology|December 5, 2017
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapyXin Chen, Christof Bernemann, Yuri Tolkach, et al.
Scientific Reports|May 12, 2018
Genomic features of renal cell carcinoma with venous tumor thrombusGregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, et al.
Nature Communications|June 14, 2016
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneityRouven Hoefflin, Bernd Lahrmann, Gregor Warsow, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axisAparna Rao, Xiaoran Zhang, Anthony R Cillo, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Scientific Reports|May 18, 2022
Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerabilityDonna M Lee, Angela Sun, Sneha S Patil, et al.
Scientific Reports|March 22, 2020
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cellsJessica L Rausch, Areej A Ali, Donna M Lee, et al.
Clinical Sarcoma Research|March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
Urologic Oncology|July 18, 2020
Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53Adam Kaczorowski, Yanis Tolstov, Michael Falkenstein, et al.
Cancer Research|January 4, 2014
Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumorsSergei Boichuk, Derek J Lee, Keith R Mehalek, et al.
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
Urologic Oncology|December 5, 2017
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapyXin Chen, Christof Bernemann, Yuri Tolkach, et al.
Scientific Reports|May 12, 2018
Genomic features of renal cell carcinoma with venous tumor thrombusGregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, et al.
Nature Communications|June 14, 2016
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneityRouven Hoefflin, Bernd Lahrmann, Gregor Warsow, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
All-trans retinoic acid induces durable tumor immunity in IDH-mutant gliomas by rescuing transcriptional repression of the CRBP1-retinoic acid axisAparna Rao, Xiaoran Zhang, Anthony R Cillo, et al.
Pageof 8